Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
Tango Therapeutics (TNGX) shares dropped 13% after reporting an 82% response rate for its drug combination in pancreatic cancer patients, slightly lower than June's 92%. The Phase 3 trial is not expected to start until 2027. The company had $1.0 billion in cash at the end of June and is awaiting FDA discussions on a faster approval path.
How this was made
The 30-second read
Why it matters
The updated data reduces expectations, prompting a 13% stock decline and likely further downside as investors await Phase 3 results.
Market read
The trial update is a primary disclosure that materially affects Tango's valuation and may influence peer biotech stocks.
What to watch
Long‑term survival data and safety profile were not disclosed; they could influence future valuation.
Background
Tango Therapeutics (TNGX) is developing vopimetostat combined with Revolution Medicines' daraxonrasib for MTAP‑deficient pancreatic cancer. The company has $1 billion cash and plans a Phase 3 trial in 2027.
Ticker impact
Tango Therapeutics reported Phase 1/2 data showing an 82% response rate, down from June's 92%, causing the stock to fall 13% pre‑market.
downward pressure as investors reassess the trial's upside
The data is a fresh clinical‑trial update that directly contradicts prior expectations, and the stock already dropped sharply.
Market effects
May temper enthusiasm for MTAP‑deficient pancreatic cancer programs across biotech.
Limited to U.S. biotech investors; no broader regional effect.
Modest, confined to specialty oncology sector.
Counterpoint
The 82% response still exceeds most historical benchmarks, suggesting the drug retains significant upside.
Key entities
- companyTango Therapeutics
Biotech firm reporting the trial data.
- companyRevolution Medicines
Provider of daraxonrasib, partner in the combination therapy.
